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Abstract
Background—Human coronaviruses (HCoVs) have been detected in children with upper and
lower respiratory symptoms but little is known about their relationship with severe respiratory
illness.
Objective—To compare the prevalence of HCoV species among children hospitalized for acute
respiratory illness and/or fever with asymptomatic controls and to assess the severity of outcomes
among hospitalized children with HCoV compared with other respiratory viruses.
Methods—From December 2003–April 2004 and October 2004–April 2005, we conducted
prospective, population-based surveillance of children <5 years of age hospitalized for ARI/fever
in three U.S. counties. Asymptomatic outpatient controls were enrolled concurrently. Nasal/throat
swabs were tested for HCoV species HKU1, NL63, 229E, and OC43 by RT-PCR. Specimens
from hospitalized children were also tested for other common respiratory viruses. Demographic
and medical data were collected by parent/guardian interview and medical chart review.
Results—Overall, HCoV was detected in 113 (7.6%) of 1,481 hospitalized children (83 [5.7%]
after excluding 30 cases coinfected with other viruses) and 53 (7.1%) of 742 controls. The
prevalence of HCoV or individual species was not significantly higher among hospitalized
children than controls. Hospitalized children testing positive for HCoV alone tended to be less ill
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than those infected with other viruses, while those coinfected with HCoV and other viruses were
clinically similar to those infected with other viruses alone.
Conclusion—In this study of children hospitalized for acute respiratory illness and/or fever,
HCoV infection was not associated with hospitalization or with increased severity of illness.
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INTRODUCTION
There are currently five coronaviruses (family Coronaviridae, genus Coronavirus) known to
infect humans: the four human coronaviruses (HCoVs) HKU1, NL63, 229E, OC43, and the
coronavirus responsible for severe acute respiratory syndrome (SARS-CoV). HCoVs 229E
and OC43 were discovered in the 1960s.1–3 Studies of cell and organ culture, serology, and
human volunteer challenges performed in the 1960s and 1970s demonstrated that infection
with 229E and OC43 was associated with viral replication and interference with ciliary
action, as well as upper respiratory tract illness and a marked antibody rise.4–7 Humans
infected with HCoVs displayed a wide range of symptoms, with many also asymptomatic. In
late 2002, the emergence of SARS-CoV fueled concern about the virulence and possible
unrecognized burden of illness due to HCoVs.8 Soon after the outbreak of SARS ended,
HCoVs NL63 and HKU1 were identified.9–12 Although HCoVs were typically detected
among individuals with upper respiratory illnesses (i.e., “the common cold”)4, 7, 13, 14, some
reports have suggested that they may have a role in pediatric lower respiratory infections
and hospitalizations15–18. In contrast, several recent publications that included asymptomatic
controls for comparison have questioned whether HCoVs have any role in severe respiratory
illness and hospitalization among young children.19–21 However, these studies were limited
by relatively small sample size, short study duration, and single geographic site.
The primary objective of this study was to use prospective, population-based surveillance to
compare the detection rates for HCoVs HKU1, NL63, 229E, and OC43 among children <5
years of age hospitalized for acute respiratory illness and/or fever (ARI/fever) with rates in
asymptomatic control children of similar ages over two winter seasons in three geographic
sites. In addition, the study compared the clinical characteristics between children
hospitalized with confirmed HCoV and those hospitalized with other respiratory viruses.
Finally, by combining these data with the data from three prior years of hospital surveillance
that did not include asymptomatic control children22, we describe the seasonality of HCoV
detections over five seasons.
METHODS
Study Design
ARI Surveillance in Hospitalized Children—As part of the surveillance activities of
the New Vaccine Surveillance Network (NVSN)23–25, study staff prospectively enrolled
hospitalized children <5 years of age with an admission diagnosis of ARI/fever that resided
in the 3 counties surrounding Rochester NY, Nashville TN, and Cincinnati OH, USA during
the period of October 2003 through April 2005. Hospital surveillance was conducted 4 days/
week during 2003–04, 7 days/week during the months when influenza was circulating in
each region in 2004–05 and 3–4 days/week when influenza was not circulating. Surveillance
hospitals accounted for >95% of the pediatric hospitalizations in each county. ARI
admission diagnoses included acute respiratory illness, apnea, asthma, bronchiolitis, croup,
cystic fibrosis exacerbation, febrile neonate, febrile seizure, fever without localizing signs,
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hypothermia, influenza, otitis media, other respiratory infection, paroxysmal cough,
pharyngitis, pneumonia, respiratory distress, RSV, rule-out sepsis, sinusitis, tonsillitis, upper
respiratory illness, and wheezing. Children were excluded if they had been hospitalized
during the prior 4 days, were newborns hospitalized since birth, had neutropenia from
chemotherapy, had a known non-respiratory cause for the hospitalization, or had been sick
>14 days when screened; all others were eligible. The same protocol was used to carry out
hospital surveillance at the Rochester and Nashville sites during the preceding three years.
Asymptomatic Control Enrollment—Children <5 years of age currently without ARI/
fever who resided within the 3 counties were systematically enrolled as asymptomatic
controls from 8–10 (depending on the year) large urban and suburban outpatient practices
during 2 days/week from December 2003–April 2004 and October 2004–April 2005. These
children will hereafter be referred to as “controls.” Study staff prospectively identified
eligible control children by reviewing clinic visit logs for well-child visits and spoke to the
parent/guardian to determine that the child did not currently have ARI symptoms (i.e., chief
complaints of a respiratory illness including fever, cough, earache, nasal congestion/runny
nose, shortness of breath/rapid or shallow breathing, sore throat, vomiting after cough, or
wheezing). In addition, the parent or guardian of each control child was asked to report the
most recent prior medical visit for fever or respiratory symptoms during the surveillance
period. Of the enrolled control children, 4.5% were excluded from analysis because review
of the clinical records indicated the child had signs of ARI during their visit, as noted by the
clinician who conducted their physical examination. There was no follow-up to determine
whether subjects became ill or not soon after their enrollment visit.
Data Collection—For all enrolled hospitalized and control children, study staff obtained
clinical and epidemiologic data from parent/guardian interviews and medical records using
standardized methods and collected combined nasal/throat swab specimens. Pre-existing
high risk conditions among enrolled children were identified based on the Advisory
Committee on Immunization Practices recommendations for influenza vaccination and
included history of asthma, heart disease, sickle cell anemia, cystic fibrosis, diabetes
mellitus, or neuromuscular conditions, such as seizures, cerebral palsy, or muscular
dystrophy.26 These conditions were considered present if noted in the medical record or if
the parent/guardian responded that a health care provider told them the child had the
condition. A history of asthma/wheezing included asthma, reactive airway disease, and
recurrent or chronic wheezing.
The study was approved by the Institutional Review Boards of each site and the Centers for
Disease Control and Prevention (CDC). Informed consent was obtained from each parent/
guardian before enrollment.
Research Laboratory Methods—Nasal/throat specimens were tested for HCoV using
realtime reverse-transcription polymerase chain reaction (RT-PCR) assays for HCoVs
HKU1, NL63, 229E, and OC43.19, 22 Specimens from hospitalized cases were also tested by
RT-PCR for influenza A or B virus (IV), human respiratory syncytial virus (RSV), human
parainfluenza virus 1, 2 and 3 (HPIV1–3), human metapneumovirus (HMPV), human
rhinovirus (HRV), and human bocavirus (HBoV). Asymptomatic control specimens were
not tested for other viruses.
Data Analysis
Analyses comparing HCoV infections among hospitalized children and controls and
assessing clinical factors among hospitalized children were restricted to the 5- and 7-month
periods when both cases and controls were enrolled (December 2003–April 2004 and
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October 2004–April 2005). Repeat hospitalizations/visits occurring among cases and
controls were not excluded or adjusted for in the analysis. There were eight children with a
second hospitalization or visits within 30 days of the first, and none of the children were
positive for HCoV on both occasions. Categorical data were assessed with Pearson chi-
square and Fisher’s exact tests. The medians and interquartile ranges (IQR) were calculated
for continuous variables. SAS version 9.2 was used for all analyses (SAS Institute, Cary
NC) and a 2-sided 0.05 significance level was applied for all statistical tests performed.
Comparison of HCoV Detections between Hospitalized and Control Children—
Crude unadjusted odds ratios and 95% confidence intervals (CI) were calculated using
logistic regression. Five conditional logistic regression models were also fit. One model
estimated the adjusted odds (aOR) of HCoV detection among hospitalized children versus
controls while controlling for age group (0–5, 6–11, 12–23, 24–59 months), county, and
month of hospitalization/visit. Four analogous models were fit to assess each HCoV species
separately. Differences between cases and controls were assessed both including and
excluding the hospitalized HCoV cases coinfected with IV, RSV, HPIV, or HMPV, and the
results were similar.
Clinical Outcomes among Hospitalized Children—To assess the severity of HCoV
infections relative to other respiratory viruses, the hospitalized children were divided into
three subgroups for comparison: 1) HCoV positive (HCoV+) children who were not
coinfected with IV, RSV, HPIV, or HMPV; 2) HCoV+ children who were coinfected with
either IV, RSV, HPIV, or HMPV, and 3) HCoV negative (HCoV−) children who were
infected with IV, RSV, HPIV, or HMPV.
Overall Prevalence and Seasonality of HCoV from 2000–2005—Hospital-based
surveillance for ARI/fever among children <5 years of age had been conducted during the
previous three years by the Rochester and Nashville sites utilizing the same study protocols
and testing methods (without enrolling healthy controls). The prevalence (1.8%) and clinical
features of the 19 HCoV+ children hospitalized from October 2001 through September 2003
have been previously reported.22 In the current study, the HCoV detection rates from the
previous 3 years are combined with the data gathered during 2003–2005 to describe the
prevalence and seasonality of HCoV during five seasons of active population-based
surveillance.
RESULTS
HCoV among Hospitalized Children
During the 12 months from December 2003 through April 2004 and October 2004 through
April 2005, 1610 (82%) of 1952 children hospitalized for ARI/fever were enrolled in the
study; test results were available for one or more of the four HCoV species in 1481 (92%) of
these children. Of these, 113 (7.6%) tested positive for HCoV. Among the species, OC43
was the most frequent, with 58 (3.9%) detections, followed by 26 (1.8%) NL63, 17 (1.1%)
HKU1, and 15 (1.0%) 229E. (Table 1) Three cases were infected with more than one strain
of HCoV: two with both HKU1 and OC43 and one with both NL63 and 229E.
Other Viral Infections among Hospitalized Children
Coinfections were identified in the 113 hospitalized children with HCoV infection: 7 (6%)
also tested positive for IV, 17 (15%) for RSV, 1 (1%) for HPIV1–3, 6 (6%) for HMPV, 8
(7%) for HRV, and 3 (3%) for HBoV. Rates of coinfection for the four HCoV species were:
59% for HKU1, 40% for 229E, 36% for OC43, and 23% for NL63 (not statistically
significantly different). Only one HCoV+ child was coinfected with two other respiratory
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viruses (IV and RSV). Overall, 41 (36%) had a viral coinfection and 30 of the coinfections
were with viruses known to be associated with serious ARI (IV, RSV, HPIV, and HMPV).
After excluding these 30 cases, the proportion of hospitalized children with HCoV was
5.7%. Of the 496 hospitalized children who were HCoV negative but were infected with a
virus associated with serious ARI (subgroup 3), 145 (29%) tested positive for IV, 276 (56%)
for RSV, 29 (6%) for HPIV1–3, and 72 (15%) for HMPV.
HCoV among Control Children
During the same two study periods described above, 822 (89%) of 919 asymptomatic
controls were enrolled and 742 (90%) had test results reported for HCoV. (Table 1) Of these
742 controls, 53 (7.1%) tested positive for HCoV. The most common species was OC43,
with 20 (2.7%), followed by 18 (2.4%) NL63, 12 (1.6%) HKU1, and 3 (0.4%) 229E.
Comparison of HCoV Detections between Hospitalized and Control Children
When compared with the controls, with or without excluding coinfections, significantly
higher detection rates were not observed among hospitalized cases for any HCoV or for any
of the specific HCoV species. (Table 1)
Demographic Characteristics of Hospitalized and Control Children
Among the hospitalized and control groups, respectively, no significant differences existed
in the demographic characteristics between those with and without HCoV infection (Table
2). More than half (52%) of the HCoV+ hospitalized children were <6 months of age
whereas HCoV infection among controls was more evenly distributed between the age
groups (p=0.001). However, the proportion of children with HCoV infection was not
significantly different in any age group for hospitalized children when compared with
controls (Table 3). Among those <6 months of age the difference was greater but still did not
reach statistical significance when coinfected cases were included (8.1% versus 4.8%, p-
value=0.09).
Medical History of Hospitalized and Control Children
The medical history and selected characteristics for hospitalized children and controls
positive for HCoV overall and for each HCoV species are shown in Supplemental Digital
Content 1. Among the children infected with species NL63, pre-existing high risk conditions
were more common among hospitalized children than controls (33% versus 0%, p=.01).
However, in both groups, the prevalence of high risk conditions was no different between
NL63-positive and NL63-negative children. The results were the same when the cases
coinfected with IV, RSV, HPIV, or HMPV were included, and no other significant
differences were found between HCoV+ hospitalized children compared with HCoV+
controls. Statistical comparisons were not made between cases and controls for species
HKU1 and 229E due to the small numbers in each group.
Adjusted Model Comparing HCoV Detections between Hospitalized and Control Children
Infection with any HCoV or with a specific HCoV species was not associated with
hospitalization in models controlling for age, county, and month of hospitalization/visit and
excluding hospitalized children that were coinfected with other respiratory viruses. The
aORs (CI) of HCoV detection among hospitalized children versus controls were as follows:
for all HCoV infections, 0.79 (0.53–1.17); for HKU1, 0.57 (0.23–1.44); for NL63, 0.63
(0.31–1.30); for 229E, 2.38 (0.63–9.05); and for OC43, 0.82 (0.45–1.49). The estimated
crude ORs and aORs changed little when HCoV+ coinfected hospitalized children were
included in the analyses.
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Discharge Diagnosis and Severity of Disease among Children Hospitalized with HCoV
Compared with Those Hospitalized with Other Respiratory Viruses
Children infected with respiratory viruses (IV, RSV, HPIV, or HMPV) (Table 4, subgroup 2
and 3) were more likely than children singly infected with HCoV (Table 4, subgroup 1) to
have had a discharge diagnosis of pneumonia or bronchiolitis, a hospital stay ≥3 days, or to
require supplemental oxygen, though the last difference was statistically significant only for
subgroup 3 versus subgroup 1. No statistically significant differences were observed
between the children coinfected with HCoV plus another respiratory virus (subgroup 2) and
the children infected only with another virus (subgroup 3). Coinfected children (subgroup 2)
had a discharge diagnosis of otitis media more often than those singly infected with HCoV
(subgroup1). In addition, among those singly infected with HCoV, 5 out of the 7 with a
discharge diagnosis of croup were infected with species NL63. Croup was also more
common among those singly infected with species NL63 than among those infected only
with a non-coronavirus respiratory virus (23.8% versus 5.8%, p=.001).
Overall Prevalence and Seasonality of HCoV from 2000–2005
The prevalence of HCoV varied over the five study years, with a higher proportion of
children with HCoV detected during 2000–01 and during the two seasons from 2003 to 2005
that are the focus of this study (see Figure, Supplemental Digital Content 2). The proportion
of children with HCoV detected each month was very similar among both hospitalized
children and controls (see Figure, Supplemental Digital Content 3). The most frequently
detected species, OC43, tended to emerge in fall and peak in winter whereas NL63, the next
most common species, tended to emerge in winter and peak in spring. Aside from one
cluster during the winter months of 2003–04, HKU1 was uncommon during the five
seasons. 229E was only observed during winter months and was not detected at all between
April 2001 and February 2004. No notable differences were observed in the seasonal
detection rates for HCoV between the three study sites during each of the five years of
surveillance, although the sample sizes were small (data not shown).
DISCUSSION
This is the first study that reports the frequency of the four recognized HCoV species among
hospitalized children and asymptomatic controls in several regions of the United States
during multiple years. No statistically significant increase was observed in the rates of
detection for HCoV or for any of the four individual species of HCoV among the
hospitalized cases when compared with the controls, regardless of whether the 27% of
hospitalized children who were coinfected with IV, RSV, HPIV, or HMPV, were excluded.
The children hospitalized for ARI/fever in whom HCoV alone was detected appeared to be
less severely ill than children with IV, RSV, HPIV, or HMPV infections, and the particular
association observed between species NL63 and croup was consistent with other
studies27–29. In addition, children coinfected with HCoV and other respiratory viruses were
clinically similar to those infected only with IV, RSV, HPIV, or HMPV. This suggests that
the other viruses rather than HCoV were responsible for the hospitalization.
The prevalence of HCoV species appeared episodic over the five seasons, with two years of
lower overall activity separating several years of higher activity. A similar episodic pattern
was reported by another study.7 However, a study of HCoV seasonality over 20 years that
did not include species HKU1 showed a high degree of year-to-year variability without a
clear episodic pattern.17 While we cannot ascertain a definitive epidemic pattern with five
years of data, this study confirms the variable nature of HCoV circulation using sensitive
methods of molecular detection.
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Overall, our finding of no association between HCoV infection and serious illness among
hospitalized children bolsters the findings of several prior studies.19–21 A 2004–05 study
from Thailand among patients of all ages and asymptomatic outpatient controls found no
association between HCoV infection and hospitalization for pneumonia.19 However, they
observed fewer cases, with detection rates of 1.8% among cases and 2.1% among controls,
and the number of asymptomatic controls enrolled was relatively small compared with our
study (280 over one year versus 742 over two years). A more recent study comparing
hospitalized Alaskan Native children less than three years of age and asymptomatic
community controls found HCoV detection rates were the same for cases and controls
(4%).20 In a prospective community-based birth cohort study, species 229E and OC43 were
detected at similar frequencies among symptomatic (5.5%) and asymptomatic children
(4.4%), and neither species was detected in a specimen taken during an ARI episode that
required hospitalization.21 In contrast to our study, a three-year study of pediatric and adult
inpatients and outpatients from the United Kingdom noted that 1.71% of those with lower
respiratory tract infection were singly infected with HCoV compared with 1.08% among
those with no respiratory symptoms.18 However, the age distribution and sample size for
those without symptoms were not described and a test for statistical significance was not
provided.
Limitations of our study include the fact that the three geographic areas in this study may
not be representative of the rest of the United States. Also, we did not assess bacterial
coinfections or antibiotic use, which could have impacted the clinical outcomes for those
children who were hospitalized. Our study did not collect data about respiratory symptoms
before or after enrollment. Both cases and controls may have tested positive for HCoV from
a very recent infection and developed symptoms after enrollment. Since prior studies have
noted that HCoV may be shed at least 14 days after acute infection30, 31, it is possible that
controls with HCoV detected may have been shedding HCoV from a recent, symptomatic
infection. However, this is also true for the hospitalized children, and few children with
HCoV had medically-attended visits for respiratory illness in the month prior to enrollment.
Another possible limitation is that asymptomatic children were not enrolled year-round, but
the peak periods of HCoV circulation were included. Finally, we did not test the controls for
the additional respiratory viruses for which the hospitalized children were tested.
This large prospective, multicenter, population-based study of HCoV infections among both
cases and controls over several seasons found no association between hospitalization for
ARI/fever and HCoV infection. This type of study, however, cannot rule out the possibility
that the infection was causal in a subset of the children. It is possible that host factors are of
primary importance in responding to HCoV infections, and further study of the relevance of
host or other co-factors in symptomatic illness would help move the field forward.
Furthermore, since very few studies of the known HCoVs have included a robust sample
size, multiple years, and a control group, more studies would be helpful to verify the
findings of this study. Given the low prevalence of hospitalized HCoV cases, the frequency
of viral coinfection, and the differences in yearly circulation patterns, conducting future
studies with larger numbers of cases and well-matched controls will be challenging.
However, new multipathogen PCR platforms may provide opportunities for future studies of
respiratory disease that include HCoV. Biopsy and autopsy studies with in situ identification
of HCoV and microscopic assessment of fatal cases might also help elucidate viral etiology.
Studies utilizing a variety of research strategies are needed to better delineate the role of
HCoV infections among children.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 2
Demographic characteristics of children hospitalized for ARI/fever (excluding those coinfected with IV, RSV,
HPIV and HMPV) and asymptomatic controls with and without HCoV during the 12 months when controls
were enrolled.
Hospitalized ARI Cases Asymptomatic Controls
HCoV+ HCoV− HCoV+ HCoV−
N=83 N=1368 N=53 N=689
% % % %
Age Group*
    <6 months 51.8 47.5 22.6 34.8
    6–11 months 7.2 14.3 26.4 18.9
    12–23 months 22.9 18.7 26.4 23.2
    24–59 months 18.1 19.5 24.5 23.1
Female 41.0 43.2 56.6 48.6
Race/ethnicity
    White Non-Hispanic 50.6 48.6 32.1 37.9
    Black Non-Hispanic 32.5 33.6 54.7 45.6
    Hispanic 13.3 11.0 9.4 9.0
    Other 3.6 6.8 3.8 7.1
Public Insurance or No Insurance 63.9 63.9 73.6 69.5
*
Hospitalized HCoV+ children were more likely to be in the youngest age group than asymptomatic HCoV+ controls (p<.01 by chi-square test).
All other differences between hospitalized children and asymptomatic controls or between cases or controls that were HCoV+ or HCoV− were not
statistically significant.
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Table 3
Age-specific HCoV detection rates (%) among ARI hospitalizations and asymptomatic controls during the 12
months when controls were enrolled.
Hospitalized
(Coinfections Excluded)* Asymptomatic Controls
<6 months 6.2 4.8
6–11 months 3.0 9.7
12–23 months 6.9 8.0
24–59 months 5.3 7.6
Total 5.7 7.1
*
excluding 30 cases coinfected with IV, RSV, HPIV or HMPV
Note: There were no statistically significant differences in HCoV detections between hospitalizations and controls.
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Table 4


















    Pneumonia or Bronchiolitis 26.5 *60.0 *68.1
    Croup 8.4 6.7 5.8
    Otitis Media 12.0 *30.0 17.9
Length of Stay
    Median (IQR) 2 (1) 2 (2) 2 (2)
    ≥3 days 16.9 *36.7 *35.1
    ≥6 days 6.0 3.3 9.5
Admitted to ICU 2.4 0.0 5.4
Required Mechanical Ventilation 1.2 0.0 3.2
Required Supplemental Oxygen 19.3 33.3 *47.1
*
p < 0.05 for comparison with Subgroup 1. None of the differences between Subgroup 2 and Subgroup 3 reached statistical significance.
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